ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
23.46
-0.77 (-3.18%)
At close: Feb 5, 2026, 4:00 PM EST
23.21
-0.25 (-1.07%)
After-hours: Feb 5, 2026, 7:38 PM EST
ACADIA Pharmaceuticals Market Cap
ACADIA Pharmaceuticals has a market cap or net worth of $3.97 billion as of February 5, 2026. Its market cap has increased by 33.33% in one year.
Market Cap
3.97B
Enterprise Value
3.18B
1-Year Change
33.33%
Ranking
Category
Stock Price
$23.46
Market Cap Chart
Since May 27, 2004, ACADIA Pharmaceuticals's market cap has increased from $112.80M to $3.97B, an increase of 3,418.62%. That is a compound annual growth rate of 17.83%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 4, 2026 | 4.10B | -9.28% |
| Dec 31, 2025 | 4.52B | 48.00% |
| Dec 31, 2024 | 3.05B | -40.60% |
| Dec 29, 2023 | 5.14B | 99.41% |
| Dec 30, 2022 | 2.58B | -31.29% |
| Dec 31, 2021 | 3.75B | -55.85% |
| Dec 31, 2020 | 8.50B | 28.98% |
| Dec 31, 2019 | 6.59B | 225.79% |
| Dec 31, 2018 | 2.02B | -45.92% |
| Dec 29, 2017 | 3.74B | 7.07% |
| Dec 30, 2016 | 3.49B | -2.91% |
| Dec 31, 2015 | 3.60B | 13.57% |
| Dec 31, 2014 | 3.17B | 39.50% |
| Dec 31, 2013 | 2.27B | 762.44% |
| Dec 31, 2012 | 263.30M | 361.93% |
| Dec 30, 2011 | 57.00M | 20.76% |
| Dec 31, 2010 | 47.20M | -6.53% |
| Dec 31, 2009 | 50.50M | 51.20% |
| Dec 31, 2008 | 33.40M | -91.84% |
| Dec 31, 2007 | 409.20M | 56.24% |
| Dec 29, 2006 | 261.90M | 13.18% |
| Dec 30, 2005 | 231.40M | 102.63% |
| Dec 31, 2004 | 114.20M | 1.24% |
| May 27, 2004 | 112.80M | - |
View and export this data all the way back to 2004. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Amicus Therapeutics | 4.48B |
| Apogee Therapeutics | 4.38B |
| TG Therapeutics | 4.26B |
| Corcept Therapeutics | 4.22B |
| CG Oncology | 4.19B |
| Arcellx | 4.01B |
| ADMA Biologics | 3.92B |
| Terns Pharmaceuticals | 3.92B |